PMV Pharmaceuticals Inc (PMVP)

Currency in USD
1.270
-0.035(-2.68%)
Closed·
1.2700.000(0.00%)
·
Earnings results expected in 12 days
PMVP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2551.330
52 wk Range
1.0201.910
Key Statistics
Prev. Close
1.305
Open
1.3
Day's Range
1.255-1.33
52 wk Range
1.02-1.91
Volume
171K
Average Volume (3m)
660.49K
1-Year Change
-18.5897%
Book Value / Share
1.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PMVP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.200
Upside
+230.71%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

PMV Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.200
(+230.71% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy5.00+293.70%-MaintainSep 08, 2026
Ladenburg Thalmann
Buy3.00+136.22%-New CoverageJul 08, 2026
Oppenheimer
Buy5.00+293.70%6.00MaintainMay 13, 2026
Evercore ISI
Buy4.00+214.96%16.00MaintainApr 10, 2026
Craig-Hallum
Buy4.00+214.96%6.00MaintainNov 13, 2025

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
-0.34 / -0.40
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PMVP Income Statement

Compare PMVP to Peers and Sector

Metrics to compare
PMVP
Peers
Sector
Relationship
P/E Ratio
−1.3x−2.2x−0.3x
PEG Ratio
−0.14−0.290.00
Price/Book
1.3x4.3x2.6x
Price / LTM Sales
-12.2x2.9x
Upside (Analyst Target)
230.7%223.3%65.5%
Fair Value Upside
Unlock16.3%9.5%Unlock

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.34M8.39%8.05M
Other Institutional Investors
53.12M70.34%67.46M
Public Companies & Retail Investors
16.06M21.27%20.40M
Total
75.51M100.00%95.9M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Samsara BioCapital LLC9.59%7,240,0009,195
BML Capital Management, LLC7.06%5,330,0006,769

People Also Watch

9.605
GOSS
+1.53%
3.630
PRLD
+0.83%
23.34
TNGX
-16.43%
1.440
ADCT
-10.00%

FAQ

What Is the PMV (PMVP) Stock Price Today?

The PMV stock price today is 1.270 USD.

What Stock Exchange Does PMV Trade On?

PMV is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for PMV?

The stock symbol for PMV is "PMVP."

What Is the PMV Market Cap?

As of today, PMV market cap is 98.540M USD.

What Is PMV's Earnings Per Share (TTM)?

The PMV EPS (TTM) is -1.41.

When Is the Next PMV Earnings Date?

PMV will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is PMVP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has PMV Stock Split?

PMV has split 0 times.

How Many Employees Does PMV Have?

PMV has 54 employees.

What is the current trading status of PMV (PMVP)?

As of Oct 24, 2026, PMV (PMVP) is trading at a price of 1.270 USD, with a previous close of 1.305 USD. The stock has fluctuated within a day range of 1.255 USD to 1.330 USD, while its 52-week range spans from 1.020 USD to 1.910 USD.

What Is PMV (PMVP) Price Target According to Analysts?

The average 12-month price target for PMV is 4.200 USD, with a high estimate of 5 USD and a low estimate of 3 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +230.71% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.